Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 27;29(8):2099–2109. doi: 10.1038/s41591-023-02452-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023, corrected publication 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a, Waterfall plot showing maximum change in target lesion size from baseline in evaluable patients (n = 30) as assessed by BICR. Bars are colored according to DLs. ^* Patients 2 and 22 had an unconfirmed PR; ⁺ patient 14 had an unconfirmed PR by local investigator assessment; ^{^} patient 3 showed more than 30% regression of target lesions on a 6-month CT scan but also a new lesion that prevented the patient from achieving a PR. CHO, cholangiocarcinoma; OVA, ovarian cancer. b, Swimmer plot showing best responses of each patient over time, assessed according to RECIST version 1.1. ^* confirmed PR. c,d, Changes in circulating surrogate markers of tumor response. Waterfall plots showing best response (% change from baseline) and SMRPs as measured in plasma using the MESOMARK assay (c) and MPF as measured in plasma using an ELISA assay (d). Responders (partial or complete response) and non-responders (SD and PD) are indicated by color-coded bars. FU, follow-up.

Source data